In this video, Michael Blackton, VP QA CMC and John Lunger Chief Patient Supply Officer at Adaptimmune talked to Cell & Gene’s Chief Editor, Erin Harris, about COVID-19’s impact on the cell and gene sector.
Adaptimmune is an autologous cell therapy company that develops novel cell therapies for people with cancer. You’ll see them discuss how COVID-19 has impacted the cell and gene sector to date and how the sector responded to the pandemic. They discussed the sector before COVID-19 and what “the after” looks like for CGTs. And, of course, what this pandemic means for the patient.